세계의 천식 및 COPD 치료제 시장 보고서 : 동향, 예측 및 경쟁 분석(-2030년)

Asthma and COPD Drugs Trends and Forecast

The future of the global asthma and COPD drugs market looks promising with opportunities in the asthma and COPD markets. The global asthma and COPD drugs market is expected to reach an estimated $40.8 billion by 2030 with a CAGR of 4.3% from 2024 to 2030. The major drivers for this market are improvements in treating respiratory conditions and the introduction of new products, rising interest in targeted medicines and biologics, as well as, urbanization and an aging population on the rise.

A more than 150-page report is developed to help in your business decisions.

Asthma and COPD Drugs by Segment

The study includes a forecast for the global asthma and COPD drugs by diseases, medication class, and region.

Asthma and COPD Drugs Market by Diseases [Shipment Analysis by Value from 2018 to 2030]:

• Asthma
• COPD

Asthma and COPD Drugs Market by Medication Class [Shipment Analysis by Value from 2018 to 2030]:

• Combination Drugs
• Short Acting Beta Agonists
• Long Acting Beta Agonists
• Leukotriene Antagonists
• Anticholinergics
• Others

Asthma and COPD Drugs Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Asthma and COPD Drugs Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies asthma and COPD drugs companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the asthma and COPD drugs companies profiled in this report include-

• Novartis
• Glaxosmithkline
• Organon
• Boehringer Ingelheim International
• Abbott Laboratories
• AstraZeneca
• Sanofi
• Hoffmann-La Roche
• Vectura Group
• Teva Pharmaceutical Industries

Asthma and COPD Drugs Market Insights

Lucintel forecasts that combination drug will remain the largest segment over the forecast period.

North America will remain the largest region over the forecast period due to the increased frequency of asthma, the presence of significant actors in manufacturing, the tobacco smoking habit, and the region's well-established infrastructure.

Features of the Global Asthma and COPD Drugs Market

Market Size Estimates: Asthma and COPD drugs market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Asthma and COPD drugs market size by diseases, medication class, and region in terms of value ($B).

Regional Analysis: Asthma and COPD drugs market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different diseases, medication class, and regions for the asthma and COPD drugs market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the asthma and COPD drugs market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the asthma and COPD drugs market size?

Answer: The global asthma and COPD drugs market is expected to reach an estimated $40.8 billion by 2030.

Q2. What is the growth forecast for asthma and COPD drugs market?

Answer: The global asthma and COPD drugs market is expected to grow with a CAGR of 4.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the asthma and COPD drugs market?

Answer: The major drivers for this market are improvements in treating respiratory conditions and the introduction of new products, rising interest in targeted medicines and biologics, as well as, urbanization and an aging population on the rise.

Q4. What are the major segments for asthma and COPD drugs market?

Answer: The future of the global asthma and COPD drugs market looks promising with opportunities in the asthma and COPD markets.

Q5. Who are the key asthma and COPD drugs market companies?

Answer: Some of the key asthma and COPD drugs companies are as follows.

• Novartis
• Glaxosmithkline
• Organon
• Boehringer Ingelheim International
• Abbott Laboratories
• AstraZeneca
• Sanofi
• Hoffmann-La Roche
• Vectura Group
• Teva Pharmaceutical Industries

Q6. Which asthma and COPD drugs market segment will be the largest in future?

Answer: Lucintel forecasts that combination drug will remain the largest segment over the forecast period.

Q7. In asthma and COPD drugs market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to the increased frequency of asthma, the presence of significant actors in manufacturing, the tobacco smoking habit, and the region's well-established infrastructure.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the asthma and COPD drugs market by diseases (asthma and COPD), medication class (combination drugs, short acting beta agonists, long acting beta agonists, leukotriene antagonists, anticholinergics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Asthma and COPD Drugs Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Asthma and COPD Drugs Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Asthma and COPD Drugs Market by Diseases
  • 3.3.1: Asthma
  • 3.3.2: COPD
• 3.4: Global Asthma and COPD Drugs Market by Medication Class
  • 3.4.1: Combination Drugs
  • 3.4.2: Short Acting Beta Agonists
  • 3.4.3: Long Acting Beta Agonists
  • 3.4.4: Leukotriene Antagonists
  • 3.4.5: Anticholinergics
  • 3.4.6: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Asthma and COPD Drugs Market by Region
• 4.2: North American Asthma and COPD Drugs Market
  • 4.2.2: North American Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others
• 4.3: European Asthma and COPD Drugs Market
  • 4.3.1: European Asthma and COPD Drugs Market by Diseases: Asthma and COPD
  • 4.3.2: European Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others
• 4.4: APAC Asthma and COPD Drugs Market
  • 4.4.1: APAC Asthma and COPD Drugs Market by Diseases: Asthma and COPD
  • 4.4.2: APAC Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others
• 4.5: ROW Asthma and COPD Drugs Market
  • 4.5.1: ROW Asthma and COPD Drugs Market by Diseases: Asthma and COPD
  • 4.5.2: ROW Asthma and COPD Drugs Market by Medication Class: Combination Drugs, Short Acting Beta Agonists, Long Acting Beta Agonists, Leukotriene Antagonists, Anticholinergics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Asthma and COPD Drugs Market by Diseases
  • 6.1.2: Growth Opportunities for the Global Asthma and COPD Drugs Market by Medication Class
  • 6.1.3: Growth Opportunities for the Global Asthma and COPD Drugs Market by Region
• 6.2: Emerging Trends in the Global Asthma and COPD Drugs Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Asthma and COPD Drugs Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Asthma and COPD Drugs Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Novartis
• 7.2: Glaxosmithkline
• 7.3: Organon
• 7.4: Boehringer Ingelheim International
• 7.5: Abbott Laboratories
• 7.6: AstraZeneca
• 7.7: Sanofi
• 7.8: Hoffmann-La Roche
• 7.9: Vectura Group
• 7.10: Teva Pharmaceutical Industries